Score CHO and E. coli clones on one 0-10 scale during cell line development. Enter titre (1-5 g/L), specific productivity qP (20-40 pg/cell/day), viability, lactate (keep below 2 g/L) and % monomer by SEC; the scorecard ranks candidates by weighted composite score and flags borderline attributes with traffic-light thresholds. .
Score CHO clones with a weighted composite that combines performance, product quality and stability on one 0-10 scale. Collect volumetric titre (target 1-5 g/L in fed-batch), specific productivity qP (20-40 pg/cell/day), peak viable cell density, viability, lactate (keep below 2 g/L) and % monomer by SEC. Assign weights of 1-5 by programme priority, normalise each criterion so higher-is-better and lower-is-better behave consistently, then rank by weighted composite score. Add traffic-light thresholds so a clone with a borderline value on a critical attribute cannot hide behind a high total.
A CHO clone scorecard for a monoclonal antibody programme typically tracks seven metrics: volumetric titre (g/L; 1-5 g/L in fed-batch is realistic for lead clones), specific productivity qP (20-40 pg/cell/day), peak viable cell density and viability (keep above 90% through day 10), doubling time (24-36 h), lactate at harvest (below 2 g/L to avoid osmolality creep), % monomer by SEC (above 95%) and stability at PDL50 or later. Weights of 4-5 go on titre, qP and stability for commercial programmes. Bispecifics add correct-assembly %; biosimilars add similarity to the reference product.
Advance the clone with the highest weighted composite score that still clears every traffic-light threshold on critical attributes, not just the one with the highest titre. For GMP, stability over extended passage (titre and quality held from PDL0 to PDL50-60) usually matters more than a 10-20% headline titre edge in a 2-week screen. Confirm the top 1-3 clones in a scale-down bioreactor run, check product-quality attributes against the target product profile, and verify monoclonality. A clone with titre 3.5 g/L and stable % monomer at 96% is a safer GMP choice than one at 4.5 g/L that drifts to 92% monomer by PDL50.
A clone selection scorecard is a structured decision-making tool used in cell line development (CLD) to objectively rank and compare candidate clones based on multiple performance criteria. Each criterion is assigned a weight reflecting its importance, and clones are scored and ranked by their weighted composite score.
For monoclonal antibody production, the most critical criteria are: volumetric titer (g/L), specific productivity qP (pg/cell/day), product quality attributes like % monomer by SEC and charge variant profile, cell growth characteristics, and clone stability over extended passage.
Each criterion is assigned a weight (1-5). Raw values are normalized to 0-10. The Weighted Composite Score (WCS) = sum of (weight x normalized score) / sum of weights. This produces a single comparable score for objective ranking.
Higher-is-better criteria (like titer) are normalized so the highest value gets score 10. Lower-is-better criteria (like doubling time) are inverted so the lowest value gets score 10. This ensures correct contribution to the composite score.
A typical CLD campaign evaluates 6-20 lead clones in detailed characterization after initial screening. The scorecard works best with 3-20 clones where comprehensive data is available. The top 1-3 clones are usually advanced.
Traffic light thresholds define green (acceptable), amber (marginal), and red (below specification) zones for each criterion. These visual indicators help quickly identify clones with critical weaknesses even if their overall composite score is high.